Table 2:
Disease control success (DCS) rates by clinical, treatment, and biomarker parameters
| Disease Control Response (DCR) | Total | Fisher’s exact p-value1 | ||||
|---|---|---|---|---|---|---|
| Yes | No | |||||
| n | (%) | n | (%) | n | ||
| Dinutuximab Infusion schedule | 7 | (23) | 23 | (77) | 30 | 0.238 |
| 2-day schedule | ||||||
| 4-day schedule | 4 | (44) | 5 | (56) | 9 | |
| Age less than or 21 or greater at enrollment | 9 | (27) | 24 | (73) | 33 | 1.000 |
| No | ||||||
| Yes | 2 | (33) | 4 | (67) | 6 | |
| Sex | 4 | (18) | 18 | (82) | 22 | 0.158 |
| Male | ||||||
| Female | 7 | (41) | 10 | (59) | 17 | |
| Race | 7 | (26) | 20 | (74) | 27 | 0.323 |
| White | ||||||
| Black | 1 | (25) | 3 | (75) | 4 | |
| Other | 2 | (67) | 1 | (33) | 3 | |
| Unknown/ Not Reported | 1 | 4 | 5 | |||
| Ethnicity | 4 | (44) | 5 | (56) | 9 | 0.393 |
| Hispanic or Latino | ||||||
| Not Hispanic or Latino | 6 | (23) | 20 | (77) | 26 | |
| Unknown/ Not Reported | 1 | 3 | 4 | |||
| Metastatic disease at initial diagnosis. | 9 | (31) | 20 | (69) | 29 | 0.693 |
| No | ||||||
| Yes | 2 | (20) | 8 | (80) | 10 | |
| Number of recurrences prior to enrollment. | 11 | (39) | 17 | (61) | 28 | 0.017 |
| 1 | ||||||
| 2 | 0 | 11 | (100) | 11 | ||
| NKp30 isoform Final | 6 | (25) | 18 | (75) | 24 | 0.232 |
| AB | ||||||
| C | 5 | (50) | 5 | (50) | 10 | |
| no data | 0 | 5 | 5 | |||
| FCGR2A | 5 | (24) | 16 | (76) | 21 | 0.681 |
| high | ||||||
| low | 4 | (36) | 7 | (64) | 11 | |
| no data | 2 | 5 | 7 | |||
| FCGR3A | 6 | (40) | 9 | (60) | 15 | 0.448 |
| high | ||||||
| low | 4 | (22) | 14 | (78) | 18 | |
| no data | 1 | 5 | 6 | |||
| Siebert, Fc affinity profile (20) | 3 | (33) | 6 | (67) | 9 | 0.685 |
| high | ||||||
| low | 6 | (26) | 17 | (74) | 23 | |
| no data | 2 | 5 | 7 | |||
1:
Excluding categories Unknown / Not reported or no data.